Furthermore, murine and human leukemic cells require glycolysis and combinatorial inhibition of CDK6 together with the glycolysis regulator 2-deoxy-D-glucose (2-DG) point at a novel therapeutic treatment strategy for BCR::ABL1+ ALL and chronic myeloid leukemia (CML) patients. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.